{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T15:58:18Z","timestamp":1785167898170,"version":"3.55.0"},"reference-count":16,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T00:00:00Z","timestamp":1704672000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Pharm in Drug Dev"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Pritelivir is a helicase\u2010primase inhibitor active against HSV. Two human mass balance trials (a multiple\u2010dose trial and a single\u2010dose trial) were performed to characterize the absorption, distribution, metabolism, and excretion of 100\u00a0mg oral pritelivir combined with a single microdose of <jats:sup>14<\/jats:sup>C\u2010pritelivir. Blood, urine, and feces samples were collected up to 26 days postdose. The plasma half\u2010life of pritelivir was 63\u201067 hours. Overall, 92% and 66% of the administered dose was recovered in the multiple and single dose trials, respectively. The low recovery after the single dose (66%) was most likely related to the formulation used. The major metabolic pathway was amide hydrolysis leading to amino thiazole sulfonamide (ATS) and pyridinyl phenyl acetic acid (PPA). In plasma, pritelivir, ATS, PPA, and PPA\u2010acyl glucuronide accounted for 40.6%, 9.4%, 5.1%, and 0.2% of total radioactivity. More than 90% of drug\u2010related material was eliminated 624 hours postdose. The majority was excreted in urine (75% and 77%), followed by feces (16% and 23%). The main components in urine were PPA\u2010acyl glucuronide (and its isomers), ATS, and its N\u2010demethylated isomers. Only minor metabolites were observed in feces. In conclusion, the major metabolic pathways of pritelivir have been identified with the primary excretion route being renal.<\/jats:p>","DOI":"10.1002\/cpdd.1358","type":"journal-article","created":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T10:39:56Z","timestamp":1704710396000},"page":"389-403","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Mass Balance and Metabolite Profile after Single and Multiple Oral Doses of Pritelivir in Healthy Subjects"],"prefix":"10.1002","volume":"13","author":[{"given":"Susanne","family":"Bonsmann","sequence":"first","affiliation":[{"name":"AiCuris Anti\u2010infective Cures AG  Wuppertal Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"McCormick","sequence":"additional","affiliation":[{"name":"Aicuris Anti\u2010infective Cures AG (Retired)  Wuppertal Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Pausch","sequence":"additional","affiliation":[{"name":"Present affiliation: BioNTech SE  Mainz Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiel","family":"de Vries","sequence":"additional","affiliation":[{"name":"Molenpad ClinPharm Support  Weesp The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Sumner","sequence":"additional","affiliation":[{"name":"AiCuris Anti\u2010infective Cures AG  Wuppertal Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Birkmann","sequence":"additional","affiliation":[{"name":"AiCuris Anti\u2010infective Cures AG  Wuppertal Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Zimmermann","sequence":"additional","affiliation":[{"name":"AiCuris Anti\u2010infective Cures AG  Wuppertal Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Kropeit","sequence":"additional","affiliation":[{"name":"AiCuris Anti\u2010infective Cures AG  Wuppertal Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,1,8]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2013.08.024"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.4155\/fmc.13.192"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.6.1766-1772.2002"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02641-14"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1065"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm0402-392"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.2c00668"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1177\/09564624211006568"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkac165"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1241"},{"key":"e_1_2_8_12_1","unstructured":"WorkowskiK AlbrechtJ AveryR et\u00a0al.Pritelivir in immunocompromised patients with mucocutaneous acyclovir resistant herpes simplex virus infections first case series. Presented at ID Week Sept 29\u2212Oct 03 2021."},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01732-22"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00216-003-2348-5"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.4.8.1021"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/03602530600952172"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2014.897328"}],"container-title":["Clinical Pharmacology in Drug Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.1358","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T06:15:50Z","timestamp":1716358550000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/cpdd.1358"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,8]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["10.1002\/cpdd.1358"],"URL":"https:\/\/doi.org\/10.1002\/cpdd.1358","archive":["Portico"],"relation":{},"ISSN":["2160-763X","2160-7648"],"issn-type":[{"value":"2160-763X","type":"print"},{"value":"2160-7648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,8]]},"assertion":[{"value":"2023-08-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-08","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}